Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Predicting Molecular Geometry02:27

Predicting Molecular Geometry

45.8K
VSEPR Theory for Determination of Electron Pair Geometries
45.8K
Prediction Intervals01:03

Prediction Intervals

3.4K
The interval estimate of any variable is known as the prediction interval. It helps decide if a point estimate is dependable.
However, the point estimate is most likely not the exact value of the population parameter, but close to it. After calculating point estimates, we construct interval estimates, called confidence intervals or prediction intervals. This prediction interval comprises a range of values unlike the point estimate and is a better predictor of the observed sample value, y. 
3.4K
Tumor Progression02:07

Tumor Progression

7.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.4K
End Point Prediction: Gran Plot01:07

End Point Prediction: Gran Plot

1.2K
A Gran plot is used to predict the equivalence volume or endpoint of a potentiometric or acid-base titration without reaching the endpoint. Typically, titration data is collected as a function of the titrant's volume up to a point less than the equivalence volume and then transformed into a linear format. The straight line is extended to the x-axis, indicating the necessary titrant volume to achieve the equivalence point.
For potentiometric titration, the Gran plot is created by plotting...
1.2K
Sensitivity, Specificity, and Predicted Value01:13

Sensitivity, Specificity, and Predicted Value

1.3K
In healthcare diagnostics, laboratory tests play a crucial role in identifying and diagnosing a wide range of medical conditions. However, interpreting test results is not always straightforward. An abnormal test result does not always confirm the presence of a disease, just as a normal result does not guarantee its absence. To assess the reliability of these diagnostic tools, healthcare practitioners rely on two key statistical indicators: sensitivity and specificity.
Sensitivity is the...
1.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial.

Blood neoplasia·2026
Same author

Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features.

Nature cancer·2025
Same author

Patients with AML and an IDH2-R172 mutation exhibit a unique initial response to intensive chemotherapy induction.

Blood advances·2025
Same author

Hematopoietic cell transplantation soon after first relapse in acute myeloid leukemia - the CONS.

Haematologica·2025
Same author

CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study.

British journal of haematology·2024
Same author

Correction: Placental expanded mesenchymal-like cells (PLX-R18) for poor graft function after hematopoietic cell transplantation: A phase I study.

Bone marrow transplantation·2024
Same journal

CAR-T cell therapy for multiple myeloma: An update on the current state and future potential.

Best practice & research. Clinical haematology·2025
Same journal

Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.

Best practice & research. Clinical haematology·2025
Same journal

Immune therapy of haematological cancers.

Best practice & research. Clinical haematology·2025
Same journal

Advances in NK cell therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Adoptive cellular therapies in multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Bispecific T-cell engager therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
See all related articles

Related Experiment Video

Updated: Feb 2, 2026

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs
05:11

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs

Published on: May 10, 2024

1.8K

Progress and predictions: AML in 2018.

Jacob M Rowe1

  • 1Technion, Israel Institute of Technology, Haifa, Israel; Department of Hematology, Rambam Health Care Campus, Haifa, Israel; Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Department of Hematology, Shaare Zedek Medical Center, 12 Shmuel Bait St, Jerusalem, IL, 9103102, Israel.

Best Practice & Research. Clinical Haematology
|November 24, 2018
PubMed
Summary
This summary is machine-generated.

Novel targeted therapies, including FLT3, BCL2, IDH1, and IDH2 inhibitors, are transforming cancer treatment. Further research is needed to optimize their use and interpret measurable residual disease (MRD) levels for predicting relapse.

Keywords:
AMLAcute myeloid leukemiaEnasidenibFLT3GemtuzumabHistone deacetylaseIDHIvosidenibMRDMeasurable residual diseaseMidostaurinVenetoclax

More Related Videos

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.6K
A Protocol for Computer-Based Protein Structure and Function Prediction
16:41

A Protocol for Computer-Based Protein Structure and Function Prediction

Published on: November 3, 2011

69.8K

Related Experiment Videos

Last Updated: Feb 2, 2026

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs
05:11

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs

Published on: May 10, 2024

1.8K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.6K
A Protocol for Computer-Based Protein Structure and Function Prediction
16:41

A Protocol for Computer-Based Protein Structure and Function Prediction

Published on: November 3, 2011

69.8K

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Recent advancements have introduced several novel targeted therapies for hematologic malignancies.
  • Approved agents include FLT3 inhibitor midostaurin, antibody-drug conjugate gemtuzumab ozogamicin, CPX-351, and IDH2 inhibitor enasidenib.
  • Further approvals in 2018 include BCL2 inhibitor venetoclax and IDH1 inhibitor ivosidenib.

Purpose of the Study:

  • To review the recent approvals of novel targeted agents in hematologic malignancies.
  • To highlight the ongoing need for research into optimizing the clinical application of these drugs.
  • To emphasize the importance of next-generation sequencing for measurable residual disease (MRD) assessment.

Main Methods:

  • Review of recent regulatory approvals for novel cancer therapies.
  • Discussion of emerging strategies in targeted therapy and personalized medicine.
  • Exploration of the role of measurable residual disease (MRD) in risk stratification.

Main Results:

  • Significant progress in targeted therapy approvals, including inhibitors for FLT3, IDH1, IDH2, and BCL2.
  • Introduction of novel drug delivery systems like liposomal formulations and antibody-drug conjugates.
  • Emerging importance of measurable residual disease (MRD) detection for predicting patient outcomes.

Conclusions:

  • The landscape of hematologic cancer treatment is rapidly evolving with new targeted agents.
  • Optimizing the use of these novel drugs and interpreting MRD levels are critical for improving patient outcomes.
  • Continued research is essential to fully leverage these advancements in clinical practice.